Loading color scheme

Investment

  • Following Merck acquisition of OncoImmune in Dec 2020
  • $50M strategic investment from Merck
  • Post money valuation $250M with nearly $50M cash at hand
  • Capital sufficient to fund operations through 1H 2022

 

  • ONC-392: Strong clinical data as truly safe CTLA-4 directed therapy
  • ONC-841:781 target CD24-Siglec 10 pathway: a novel “Do-Not-Eat” signal as well as ADCC/ADCP immune checkpoint
  • ONC-782, 783 and 784: Broadly targeting all major cancers
  • ONC-895: Represents a new and selective way to differentially regulate PD-L1 in tumors vs normal tissues
  • Management team has a proven track record of scientific innovation with broad experience and deep backgrounds in drug development, operations, manufacturing, FDA and regulatory bodies, business development and capital markets
  • Series B Crossover financing 1H 2021
  • IPO financing contemplated for 2H 2021
  • Prepare ONC-392 to enter registrational studies mid 2022